5/25/2026

Janusmed kön och genus

Janusmed kön och genus – Felbamat

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Felbamat

Felbamat

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Christian CA, Reddy DS, Maguire J, Forcelli PA. Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies. Pharmacol Rev. 2020;72(4):767-800.

  2. Reddy DS, Thompson W, Calderara G . Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis. Neurosci Lett. 2021;750:135753.

  3. McHugh JC, Delanty N. Epidemiology and classification of epilepsy: gender comparisons. Int Rev Neurobiol. 2008;83:11-26.

  4. Christensen J, Vestergaard M, Pedersen MG, Pedersen CB, Olsen J, Sidenius P. Incidence and prevalence of epilepsy in Denmark. Epilepsy Res. 2007;76(1):60-5.

  5. Christensen J, Kjeldsen MJ, Andersen H, Friis ML, Sidenius P. Gender differences in epilepsy. Epilepsia. 2005;46(6):956-60.

  6. Taloxa (felbamate). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2021-09-01, cited 2026-03-18].

  7. Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2005;39(3):956-60.

  8. Widdess-Walsh P, Dlugos D, Fahlstrom R, Joshi S, Shellhaas R, Boro A, Sullivan J, Geller E; EPGP Investigators. Lennox-Gastaut syndrome of unknown cause: phenotypic characteristics of patients in the Epilepsy Phenome/Genome Project. Epilepsia. 2013;54(11):1898-904.

  9. Felbatol (felbamate). Drug label. DailyMed [www]. US National Library of Medicine. [updated 2025-08-01, cited 2026-03-18].

  10. Graves NM, Ludden TM, Holmes GB, Fuerst RH, Leppik IE. Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials. Pharmacotherapy. 1989;9(6):372-6.

  11. Richens A, Banfield CR, Salfi M, Nomeir A, Lin CC, Jensen P, Affrime MB, Glue P. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol. 1997;44(2):129-34.

  12. Rabinowicz S, Schreiber T, Heimer G, Bar-Yosef O, Nissenkorn A, E ZD, Arkush L, Hamed N, Ben-Zeev B, Tzadok M. Felbamate for pediatric epilepsy-should we keep on using it as the last resort? Front Neurol. 2022;13:979725.

  13. Pellock JM. Felbamate. Epilepsia. 1999;40(Suppl 5):57-62.

  14. Petrović S, Kovačević M, Kovačević SV, Miljković B. Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase. Expert Opin Drug Metab Toxicol. 2024;20(3):165-173.

  15. Saano V, Glue P, Banfield CR, Reidenberg P, Colucci RD, Meehan JW, Haring P, Radwanski E, Nomeir A, Lin CC, et al . Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther. 1995;5(58):523-31.

  16. Felbamate: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -PSUSA/00010155/201609. European Medicines Agency (EMA) [www]. [updated 2017-09-18, cited 2026-03-17].

  17. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]

  1. Christian CA, Reddy DS, Maguire J, Forcelli PA. Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies. Pharmacol Rev. 2020;72(4):767-800.
  2. Reddy DS, Thompson W, Calderara G . Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis. Neurosci Lett. 2021;750:135753.
  3. McHugh JC, Delanty N. Epidemiology and classification of epilepsy: gender comparisons. Int Rev Neurobiol. 2008;83:11-26.
  4. Christensen J, Vestergaard M, Pedersen MG, Pedersen CB, Olsen J, Sidenius P. Incidence and prevalence of epilepsy in Denmark. Epilepsy Res. 2007;76(1):60-5.
  5. Christensen J, Kjeldsen MJ, Andersen H, Friis ML, Sidenius P. Gender differences in epilepsy. Epilepsia. 2005;46(6):956-60.
  6. Taloxa (felbamate). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2021-09-01, cited 2026-03-18].
  7. Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2005;39(3):956-60.
  8. Widdess-Walsh P, Dlugos D, Fahlstrom R, Joshi S, Shellhaas R, Boro A, Sullivan J, Geller E; EPGP Investigators. Lennox-Gastaut syndrome of unknown cause: phenotypic characteristics of patients in the Epilepsy Phenome/Genome Project. Epilepsia. 2013;54(11):1898-904.
  9. Felbatol (felbamate). Drug label. DailyMed [www]. US National Library of Medicine. [updated 2025-08-01, cited 2026-03-18].
  10. Graves NM, Ludden TM, Holmes GB, Fuerst RH, Leppik IE. Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials. Pharmacotherapy. 1989;9(6):372-6.
  11. Richens A, Banfield CR, Salfi M, Nomeir A, Lin CC, Jensen P, Affrime MB, Glue P. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol. 1997;44(2):129-34.
  12. Rabinowicz S, Schreiber T, Heimer G, Bar-Yosef O, Nissenkorn A, E ZD, Arkush L, Hamed N, Ben-Zeev B, Tzadok M. Felbamate for pediatric epilepsy-should we keep on using it as the last resort? Front Neurol. 2022;13:979725.
  13. Pellock JM. Felbamate. Epilepsia. 1999;40(Suppl 5):57-62.
  14. Petrović S, Kovačević M, Kovačević SV, Miljković B. Hepatotoxicity of newer antiseizure medications in children: an overview and disproportionality analysis of VigiBase. Expert Opin Drug Metab Toxicol. 2024;20(3):165-173.
  15. Saano V, Glue P, Banfield CR, Reidenberg P, Colucci RD, Meehan JW, Haring P, Radwanski E, Nomeir A, Lin CC, et al . Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther. 1995;5(58):523-31.
  16. Felbamate: CMDh scientific conclusions and grounds for variation, amendments to the Product Information and timetable for the implementation -PSUSA/00010155/201609. European Medicines Agency (EMA) [www]. [updated 2017-09-18, cited 2026-03-17].
  17. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]